logo
logo

Surge Therapeutics Raises $32M Series B Financing To Advance Intraoperative Immunotherapy To Improve Cancer Patient Survival Outcomes Post-Surgery

Jul 19, 2023•almost 2 years ago

Amount Raised

$32 Million

Round Type

series b

CambridgeBiotechnologyHealth CareTherapeutics

Investors

Pitango Health TechKhosla VenturesIntuitive VenturesCancer Research InstituteCamford CapitalAlumni Ventures8 VcPiedmont CapitalKd T VenturesBioluminescence Ventures

Description

SURGE Therapeutics (SURGE), a biotech company pioneering the delivery of immunotherapy during cancer surgery, announced today the completion of a $32 million Series B financing led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango HealthTech.

Company Information

Company

SURGE Therapeutics

Location

Cambridge, Maryland, United States

About

SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People